Catalytic organometallic anticancer complexes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Organometallic complexes offer chemistry that is not accessible to purely organic molecules and, hence, potentially new mechanisms of drug action. We show here that the presence of both an iodido ligand and a σ-donor/π-acceptor phenylazopyridine ligand confers remarkable inertness toward ligand substitution on the half-sandwich “piano-stool” ruthenium arene complexes [(η 6 -arene)Ru(azpy)I] + (where arene = p -cymene or biphenyl, and azpy = N , N -dimethylphenyl- or hydroxyphenyl-azopyridine) in aqueous solution. Surprisingly, despite this inertness, these complexes are highly cytotoxic to human ovarian A2780 and human lung A549 cancer cells. Fluorescence-trapping experiments in A549 cells suggest that the cytotoxicity arises from an increase in reactive oxygen species. Redox activity of these azopyridine Ru II complexes was confirmed by electrochemical measurements. The first one-electron reduction step (half-wave potential −0.2 to −0.4 V) is assignable to reduction of the azo group of the ligand. In contrast, the unbound azopyridine ligands are not readily reduced. Intriguingly the ruthenium complex acted as a catalyst in reactions with the tripeptide glutathione (γ- l -Glu- l -Cys-Gly), a strong reducing agent present in cells at millimolar concentrations; millimolar amounts of glutathione were oxidized to glutathione disulfide in the presence of micromolar ruthenium concentrations. A redox cycle involving glutathione attack on the azo bond of coordinated azopyridine is proposed. Such ligand-based redox reactions provide new concepts for the design of catalytic drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, many chemotherapeutics are known to increase the production of ROS in cancer cells.14, 15, 16”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [16]
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766 · cited 1×
“The concentration of the complexes that caused 50% inhibition of the growth (IC50) was determined by using the sulforhodamine-B (SRB) assay (39) as reported (13).”
MethodMeister, A., & Anderson, M. E. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.003431 · Cited by 5,680
Wang, H., & Joseph, J. A. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00107-0 · Cited by 2,346
Halliwell, B., & Whiteman, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705776 · Cited by 2,238 · cited 2×
“This probe measures general oxidative stress (20).”
Hwang, T. L., & Shaka, A. J. (1995) · Journal of Magnetic Resonance, Series A · doi:10.1006/jmra.1995.1047 · Cited by 1,898
Fluorescence probes used for detection of reactive oxygen species
Gomes, A., Fernandes, E., & Lima, J. L. F. C. (2005) · Journal of Biochemical and Biophysical Methods · doi:10.1016/j.jbbm.2005.10.003 · Cited by 1,844 · cited 3×
“Excessive ROS generation inside cells is harmful, causing oxidation of biomolecules such as lipids, cell membranes, proteins, and DNA, and giving rise to oxidative stress (30).”
Aruoma, O. I., Halliwell, B., Hoey, B. M., & Butler, J. (1989) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(89)90066-x · Cited by 1,772 · cited 15×
“On the basis that GSH is the primary cellular antioxidant, it seems likely that the depletion of antioxidants is the primary mechanism by which ROS levels are increased and by which oxidative stress occurs in the systems studied here.”
InfluentialNew metal complexes as potential therapeutics
Zhang, C. X., & Lippard, S. J. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00081-4 · Cited by 946 · cited 1×
“Many examples are known of metal anticancer complexes containing metal–halide bonds that are activated in cells by hydrolysis and subsequently bind to DNA as a target, for example, PtII diam(m)ine complexes, including the drug cisplatin (21), and diamino RuII arene complexes (22).”
The role of glutathione in cancer
Balendiran, G. K., Dabur, R., & Fraser, D. (2004) · Cell Biochemistry and Function · doi:10.1002/cbf.1149 · Cited by 927
Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
Morris, R. E., Aird, R. E., del Socorro Murdoch, P., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010051m · Cited by 787
Self-citation
Research works printed but not linked: 2
- PT Beurskens, et al. The DIRDIF-99 program system (Crystallography Laboratory, University of Nijmegen, The Netherlands, 1999).
- GM Sheldrick SHELXL-97 (University of Göttingen, Göttingen, Germany, 1997).
Cited by
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
“For example, Sheldrick et al. have used an automated multidimensional protein identification technology (MudPIT), which combined biphasic liquid chromatography with electrospray ionization tandem mass spectrometry (MS/MS) to analyze tryptic peptides from Escherichia coli cells, which were first treated with [(6-p-cyme…”
BackgroundReactive Oxygen Species in Cancer: Current Findings and Future Directions
Nakamura, H., & Takada, K. (2021) · Cancer Science · doi:10.1111/cas.15068 · Cited by 1,027
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Self-citationAreneruthenium complexes as anticancer agents
Süß‐Fink, G. (2009) · Dalton Transactions · doi:10.1039/b916860p · Cited by 652
Metadata
- Authors
- Dougan, S. J., Habtemariam, A., McHale, S. E., Parsons, S., & Sadler, P. J.
- Affiliations
- University of Edinburgh (GB)
- University of Warwick (GB)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-08-19
- Volume
- 105
- Issue
- 33
- Pages
- 11628-11633
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2503924
- OpenAlex
- W2053726603
- Cited by
- 303
- References
- 40
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 12 · 2023: 16 · 2022: 13 · 2021: 21 · 2020: 25 · 2019: 25 · 2018: 22 · 2017: 17 · 2016: 28 · 2015: 18 · 2014: 15 · 2013: 17 · 2012: 18
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- University of Warwick
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Physical Sciences › Chemistry › Organic Chemistry › Organometallic Complex Synthesis and Catalysis
- Physical Sciences › Chemistry › Inorganic Chemistry › Inorganic and Organometallic Chemistry
- Keywords
- ruthenium(II) arene complexes, reactive oxygen species, glutathione oxidation, glutathione disulfide, azo bond reduction, redox cycling, cytotoxicity, A549 cells, A2780 cells
- MeSH terms
- Antineoplastic Agents, Catalysis, Cell Survival, Electrochemistry, Glutathione, Humans, Neoplasms, Organometallic Compounds, Oxidation-Reduction, Structure-Activity Relationship, Molecular Structure, Reactive Oxygen Species, Ruthenium Compounds, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Catalytic organometallic anticancer complexes. https://app.cochat.ai/papers/10.1073/pnas.0800076105
- The paper
- Dougan, S. J., Habtemariam, A., McHale, S. E., Parsons, S., & Sadler, P. J. (2008). Catalytic organometallic anticancer complexes. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0800076105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.